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1561-5413/Copyright ª 2015, Hong KoSummary Chronic infection with hepatitis B virus (HBV) leads to adverse clinical outcomes in
renal transplant recipients (RTRs) because of increased hepatic complications. The use of oral
nucleos(t)ide analogs (NAs) has brought the management of HBV infection in RTRs to a new
paradigm. Lamivudine (LAM) can effectively suppress HBV DNA levels, normalize liver biochem-
istry, and significantly improve short- and long-term patient survival in HBsAg-positive RTRs.
However, it has the burden of high drug resistance. The prevention and management of
drug-resistant HBV infection in RTRs has emerged as an important clinical issue. In treat-
ment-naı¨ve hepatitis B surface antigen (HBsAg)-positive RTRs, ETV has demonstrated high ef-
ficacy, low resistance rates, and favorable tolerability. Entecavir can also significantly improve
transaminasemia in LAM-resistant patients, although the virological response is relatively
modest in comparison to the virological response in treatment-naı¨ve patients. Adefovir
(ADV) and tenofovir (TDF) are viable options for LAM-resistant HBV infection in RTR; however,
their use in patients with moderate to severe allograft dysfunction entails a balance between
the potential risk and benefit, the appropriate dose adjustment, and allograft function moni-
toring for nephrotoxicity. The long-term patient survival of HBsAg-positive RTRs has signifi-
cantly improved with the progress in these effective antiviral treatments, and is
approaching the survival rate of their HBsAg-negative counterparts. Many efficacious options
of first-line and rescue therapies are available, but the choice of NA in HBsAg-positive RTR
should take into consideration antiviral potency, drug resistance pattern, renal allograft func-
tion, and the cost and availability of drugs in different localities.
乙型肝炎病毒 (HBV) 慢性感染所導致的肝臟併發症，並不利於腎臟移植接受者 (RTR) 的預後，因
此口服核苷/核苷酸類似物 (NA) 療法佔有重要的角色。對於 HBsAg 陽性的腎臟移植接受者，la-
mivudine (LAM) 一方面可有效抑制 HBV DNA 的水平及促進肝臟生化的正常化，同時更能顯著改
善病人的短期和長期存活率；然而與之相關的抗藥性仍然居高不下。事實上，RTR 間抗藥性 HBV; ALT Z alanine transaminase; DNA Z deoxynucleic acid; ETV Z entecavir; HBeAgZ hepatitis B e-
antigen; HBV Z hepatitis B virus; HIV Z human immunodeficiency virus; LAM Z lamivudine; NA Z
nsplant recipient; TDF Z tenofovir.
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Hepatitis B treatment in renal transplant patients 9感染的預防與處置已成為一個重大的臨床課題。在初治的 HBsAg陽性 RTR之間，entecavir (ETV)
的功效已獲得證實，兼具低抗藥性與良好耐受性。在 LAM抗藥病人間，ETV可明顯改善肝酵素上
升，雖然病毒學反應稍低於初治病人之間。誠然，對於已出現 LAM 抗藥性 HBV 感染的 RTR，
adefovir (ADV) 或 tenofovir (TDF) 均為可行用藥，然而基於腎臟毒性問題，在植入腎臟呈中至
重度功能障礙的患者間，其使用必須加倍謹慎，並在有需要時作出適當的劑量調整及腎功能監
測。隨著有效抗病毒療法的實施，HBsAg 陽性 RTR 的長期存活已取得明顯改善，並接近 HBsAg
陰性患者的存活水平。在目前已有多種第一線與救援用藥可供 HBsAg 陽性 RTR 應用之下，NA
的選擇因素應包括抗病毒效力、抗藥狀況、對植入腎臟的影響、藥物價格、供應是否充足等。Introduction
Chronic infection with hepatitis B virus (HBV) is associated
with adverse clinical outcomes in renal transplant re-
cipients (RTRs). These undesirable outcomes stem from
early complications such as fulminant hepatitic flares or
fibrosing cholestatic hepatitis, and from late complications
such as cirrhosis, decompensated liver failure, or hepato-
cellular carcinoma.1e8 Universal HBV immunization pro-
grams, prudent infection control measures and transfusion
practices in dialysis units, increased use of erythropoietin
stimulating agents, meticulous matching of donor-recipient
HBV status, and the use of HBV hyperimmunoglobulins
during the perioperative period have substantially
contributed to reducing HBV transmission in dialysis pa-
tients and RTRs. However, in endemic areas such as the
AsiaePacific region where the prevalence of chronic HBV
infection can be up to 10e15% in the dialysis population in
some cities,9,10 a considerable number of hepatitis B sur-
face antigen (HBsAg)-positive patients will undergo kidney
transplantation; hence, managing HBV infection in RTRs
remains an imperative clinical challenge.
In the general population, oral nucleos(t)ide analogs
(NAs) and interferon-based therapies are treatment options
with proven efficacy for chronic HBV infection. However,
the administration of interferon in RTRs was associated with
low treatment efficacy and a high incidence of precipitating
allograft dysfunction, and thus should be avoided.11,12 In
this context, oral NAs have become the mainstay of treat-
ment for HBsAg-positive RTRs. The aim of therapy is to
forestall short- and long-term hepatic complications. The
two common approaches to initiate antiviral therapies in
HBV-infected RTRs are based on commencing immunosup-
pressive treatments (i.e., the “prophylactic” approach) or
if there is evidence of imminent HBV reactivation (i.e., the
“pre-emptive” approach). Previous studies have highlighted
that administering antiviral therapy as a prophylactic
treatment or as a pre-emptive treatment in RTRs results in
much superior outcomes, compared to salvage treatment
(i.e., treatment commenced after evidence of hepatic
dysfunction).9,13 One recent retrospective study compared
“prophylactic” and “pre-emptive” initiation of lamivudine
(LAM) in HBsAg-positive RTRs, and found no statistical dif-
ference between these two approaches in preventing liver
function derangement or virological breakthrough.14 How-
ever, close monitoring of the HBV DNA level with rapid
“turn-around” time is a prerequisite to an effective and
safe “pre-emptive” strategy.
The optimal treatment duration of NAs in RTRs remain
undefined because of the paucity of data in this area. MostHBV-infected RTRs require lifelong NA administration,
although preliminary experience suggests that the cessation
of treatment may be feasible in carefully selected low-risk
patients after stable viral suppression and sufficient dura-
tion of treatment, provided that there is close surveillance
to detect a disease flare after stopping treatment.1,15 The
currently available choices of NAs for the treatment of HBV
infection locally include LAM, entecavir (ETV), telbivudine
(TBV), adefovir (ADV), and tenofovir (TDF) (Table 1). The
following discussion reviews the data on these agents for the
treatment of chronic HBV infection in RTRs.
Lamivudine
Lamivudine is a nucleoside analog of cytidine and a reverse
transcriptase inhibitor of HBV and human immunodeficiency
virus (HIV). Because LAM was the first oral NA available for
the treatment of chronic HBV infection, it has the most
extensive efficacy and safety data in HBsAg-positive RTRs.
Data from our group and other investigators have demon-
strated that using LAM in HBsAg-positive RTRs effectively
suppresses HBV DNA and significantly improves liver trans-
aminasemia.1,16,17 One meta-analysis that pooled data from
14 prospective clinical trials reports that, after approxi-
mately 14 months of LAM treatment, the rate of HBV DNA
undetectability was 91% [95% confidence interval (CI),
86e96%]; HBeAg clearance, 27% (95% CI, 16e39%); alanine
transaminase (ALT) normalization, 81% (95% CI, 70e92%);
and LAM-resistance, 18% (95% CI, 10e37%).18 The long-term
benefit of LAM treatment was also exemplified by signifi-
cantly improved patient survival in HBsAg-positive RTRs
with 10- and 20-year patient survival rates of 90% and 83%,
respectively (the patient survival was 83% and 34%,
respectively, in HBsAg-positive RTRs who have not received
antiviral therapy).1,7,19 The data thus shows that the patient
survival rate in the medium term nearly approaches that of
HBsAg-negative RTRs.19,20 However, hepatic complications
remain the cause of death in 40% of HBsAg-positive RTRs,
even in the era of effective antiviral therapies.19
Prolonged LAM administration is associated with the
progressive development of drug resistance, and the cu-
mulative resistance rate for LAM is > 60% after 5.7 years of
treatment.18,19,21,22 The emergence of LAM-resistance is
usually coupled with liver function derangement, which can
be transient or persistent and has variable severity; how-
ever, recent data from our group suggests that the devel-
opment of LAM-resistance does not significantly affect the
liver stiffness score, incidence of cirrhosis or hepatocellular
carcinoma, or patient survival during 10e14 years of
follow up.19
Table 1 Comparison of different nucleos(t)ide analogs in renal transplant recipients.
Nucleos(t)ide
analogs
Advantages Disadvantages
Lamivudine  Most extensive data on efficacy and safety in
treatment-naı¨ve HBsAg-positive RTRs
 Available data on long-term patient outcomes
 Relatively inexpensive
 High rates of resistance after prolonged
administration (>60% after 5 years
of treatment)
Adefovir  Main indication is for rescue therapy for
LAM-resistant HBV in RTRs, although it has
some efficacy in treatment-naı¨ve patients
 Nephrotoxic
 Variable and relatively modest efficacy,
especially after dosage reduction in RTRs
with allograft dysfunction
Entecavir  Effective for treatment-naı¨ve RTRs and
LAM-resistant HBsAg-positive RTRs
 Very low resistance rates in
treatment-naı¨ve patients
 Non-nephrotoxic
 More costly
 Lower efficacy and emergence of
ETV-resistance when used in LAM-resistant
subjects
Tenofovir  Potent therapy for treatment-naı¨ve RTRs
and LAM-resistant HBsAg-positive RTRs
 Very low resistance rates
 May be useful in multidrug-resistant patients
 Expensive
 Potentially nephrotoxic, especially in
patients with organ transplant or
pre-existing renal impairment
Telbivudine  Effective in treatment-naı¨ve HBsAg-positive RTRs
 Relatively low resistance rates, compared to LAM
 Non-nephrotoxic
 Lower cost, compared to other new NAs
 Relatively little clinical efficacy data
in HBsAg-positive RTRs
ADVZ adefovir; ETVZ entecavir; HBsAgZ hepatitis B surface antigen; HBVZ hepatitis B virus; LAMZ lamivudine; NAZ nucleos(t)ide
analog; RTR Z renal transplant recipient; TBV Z telbivudine; TDF Z tenofovir.
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For historical reasons, a considerable number of HBsAg-
positive RTRs have received protracted LAM treatment and
consequently developed drug resistance. This poses a sub-
stantial challenge in managing these patientsdmany
effective rescue therapies are potentially nephrotoxic and
limited efficacy and safety data are available in this area.
Prior to the availability of an alternative NA, it was a pre-
vailing practice to maintain patients on LAM, despite the
appearance of drug resistance; however, the introduction
of ADV offered the first alternative to circumvent this
clinical problem. Adefovir is a nucleotide reverse tran-
scriptase inhibitor that exhibits antiviral activity against
wild-type and LAM-resistant HBV; the primary clinical
application of ADV is for the latter microorganism.23 The
short-term efficacy of ADV as mono- or add-on therapy has
been demonstrated in RTRs.24e29 In this context, ADV
monotherapy in 11 RTRs with dosage adjustment (according
to allograft function) significantly reduced HBV DNA levels
with acceptable tolerability and no virological break-
through at 1 year.24 Other groups that have examined ADV
as an add-on therapy to LAM have reported HBV DNA
undetectability rates of 35.7%, 42.8%, and 88.0% after 12
months, 24 months, and 36 months of treatment, respec-
tively, in LAM-resistant RTRs.28,29 Furthermore, sustained
normalization of ALT and virological suppression was ach-
ieved in 92.8% of patients after 1 year of follow up.29
However, these virological responses could be variable
and relatively modest, compared to the responses of
treatment-naı¨ve participants.30 Substituting with ADV could
inhibit HBV viral replication better and improve livertransaminase levels, compared continuing LAM in HBsAg-
positive RTR (75% of patients vs. 14.3% of patients had
persistent normalization of ALT in one study); such a clin-
ical response has been sustained for at least 2 years.19
Nephrotoxicity is an important concern for ADV treat-
ment, which occurs in 30e50% of RTRs, despite dosage
modification, and may require drug discontinuation.28,29
The exact mechanism of nephrotoxicity by ADV is not well
understood, although alterations in renal tubular trans-
porter, apoptosis of renal tubular epithelial cells, and
mitochondrial toxicity have all been implicated.31 Our
experience suggests that ADV can be safely administered
without significant allograft function deterioration on
follow up in patients with a serum creatinine level below
150 mmol/L or creatinine clearances above 40 mL/min.19
However, ADV at the currently approved dose is not very
potent, compared to other agents. It remains unclear
whether its efficacy may be further compromised after
dosage reduction in patients with allograft dysfunction.Entecavir, tenofovir, and telbivudine
ETV is a deoxyguanosine analog that potently inhibits
reverse transcription during HBV replication. In treatment-
naı¨ve RTRs who expect to receive prolonged antiviral ther-
apy, ETV offers a new promise because of its efficacy in
treatment-naı¨ve and LAM-resistant patients, its very low
resistance rate, and the absence of nephrotoxicity.32e34
Recent data from our group suggests that the use of ETV
in treatment-naı¨ve RTRs significantly decrease HBV DNA
levels, and the cumulative rate of HBV DNA undetectability
Hepatitis B treatment in renal transplant patients 11was 60%, 100%, and 100% at 12 months, 24 months, and 36
months, respectively (the time-to-HBV DNA undetectability
and time-to-ALT normalization were 15.7  4.6 months and
12.6  3.7 months, respectively).35 More importantly, no
resistance to ETV emerged in treatment-naı¨ve HBsAg-
positive RTRs, after a follow up of 34.7  22.9 months.
Another recent study also corroborated our observations and
revealed that ETV treatment achieved HBV undetectability
rates of 74%, 96%, and 100% after 6 months, 12 months, and
24 months, respectively, in treatment-naı¨ve RTRs.36
In this study, ETV treatment was well tolerated and
appeared to have superior viral suppression, compared to
LAM-treated historical controls. ETV is an option for man-
aging LAM-resistant HBsAg-positive RTRs. Experience
regarding the use of ETV in RTRs who developed LAM- or
ADV-resistance has been examined in one study with 10 solid
organ transplant recipients (8 patients were RTRs).37 In this
series, ETV appreciably declined HBV DNA, and the HBV
undetectability rates were 50% in HBeAg-positive and
HBeAg-negative patients after 16.5 months of therapy. Our
recent data also showed that ETV treatment could effec-
tively suppress HBV viral replication and normalize liver
biochemistry in LAM-resistant RTRs, although the cumulative
rates of HBV undetectability were only 27%, 45%, and 45%
after 6 months, 12 months, and 24 months of treatment,
respectively.35 The allograft function also remained stable
after approximately 3 years of follow up. Similar to the
general population, the efficacy of ETV in LAM-resistant
HBsAg-positive RTRs could be variable and relatively less
effective, compared to its efficacy in treatment-naı¨ve sub-
jects.19,30,35 A higher dose of ETV (1 mg daily) is used to
treat LAM-resistant HBV infection in the general population.
However, the dosage reduction required in RTRs who have
allograft dysfunction may potentially compromise the anti-
viral efficacy. Furthermore, we also reported that genotypic
resistance to ETV emerged in two (of 10) LAM-resistant RTRs
with a surge in ALT and HBV DNA levels after 20.0  3.5
months, which suggests that vigilant monitoring is important
when ETV is used in LAM-resistant RTRs.35
TDF is a nucleotide analog that exhibits robust activity
against the viral reverse transcriptase of HIV and HBV. It
was initially licensed for the treatment of HIV infection; it
was subsequently approved for use in chronic HBV infectionFigure 1 The rates of hepatitis B virus undetectability, alanine tr
of treatment by different oral nucleos(t)ides in renal transplant rec
LAM Z lamivudine.because of its high potency and very low resistance rates
for treatment-naı¨ve patients and LAM-resistant pa-
tients.33,38 Data regarding the use of TDF in HBsAg-positive
RTRs is scarce. Daude´ et al39 showed promising short-term
efficacy on HBV viral suppression and favorable renal pro-
file at 1 year in seven solid organ transplant recipients (3
patients were RTRs) who only had partial response to other
NAs such as LAM, ADV, or ETV.39 One recent small series also
supported the efficacy and tolerability of TDF as recue
therapy in four LAM-resistant HBsAg-positive RTRs.14
Furthermore, TDF is reportedly useful for treating HBsAg-
positive RTRs with multidrug resistance.40 However, po-
tential nephrotoxicity is an important concern when using
TDF in RTRs.41 TDF overall seems less nephrotoxic than
ADV, but the mechanism of nephrotoxicity by TDF remains
poorly understood. Renal tubular epithelial cell apoptosis,
changes in renal tubular transporters, and mitochondrial
toxicity are possible mechanisms of TDF-related nephro-
toxicity.31 A history of organ transplantation and pre-
existing renal insufficiency were proposed as independent
risk factors for developing nephrotoxicity in TDF-treated
patients.42 TDF represents a highly effective antiviral op-
tion, especially for LAM-resistant patients; therefore, it will
be worthwhile to initiate formal studies in HBsAg-positive
RTRs to investigate its long-term efficacy, impact on allo-
graft function, optimal dosage adjustment, and patient
subgroups who could well tolerate this treatment.
To date, there is no data regarding the use of TBV in
RTRs. The relatively low resistance rate, absence of neph-
rotoxicity, and the relatively lower cost in comparison to
other NAs nevertheless makes TBV an attractive therapeu-
tic option for treatment-naı¨ve RTRs.43,44 Recent data in the
general population also suggest that TBV may have reno-
protective effects for patients at risk of renal impair-
ment.45 Whether such benefits can be extrapolated to RTRs
remain to be tested.Concluding remarks
The use of oral NAs has transformed the landscape of
managing HBsAg-positive RTRs, and is associated with
significantly improved short- and long-term clinicalansaminase normalization, and drug resistance after 12 months
ipients. ALTZ alanine transaminase; HBVZ hepatitis B virus;
12 D.Y.H. Yap, T.M. Chanoutcomes. The prevention and management of drug-
resistant HBV infection in RTRs remains an important clin-
ical challenge, especially because some effective thera-
peutic options also have potential nephrotoxicity. The
choice of NAs for HBsAg-positive RTRs should take into
consideration antiviral potency, drug resistance pattern,
renal allograft function, and the cost and availability of
drugs in different localities (Fig. 1). The use of antiviral
therapy constitutes an integral part of managing HBsAg-
positive RTRs, but regular surveillance for long-term he-
patic complications such as cirrhosis and liver cancer is also
very important for optimizing patient outcomes. In this
context, current data suggest that monitoring with ultra-
sonography and alpha-fetoprotein level assays can facili-
tate early detection of hepatocellular carcinoma, which
will render patients more amenable to tumor resection and
thus enhance patient survival.46e48Conflicts of interest
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